Vaccine Adjuvants
| Autor Corporativo: | |
|---|---|
| Otros Autores: | , |
| Formato: | eBook |
| Lenguaje: | English |
| Publicado: |
Totowa, NJ :
Humana Press : Imprint: Humana,
2006.
|
| Edición: | 1st ed. 2006. |
| Colección: | Infectious Disease
|
| Materias: | |
| Acceso en línea: | https://doi.org/10.1007/978-1-59259-970-7 |
Tabla de Contenidos:
- Microbial Pathogenesis and the Discovery of Toll-Like Receptor Function
- Dendritic Cells
- Achieving Transcriptional Specificity in NF-?B-Dependent Inflammatory Gene Expression
- Adjuvants and the Initiation of T-Cell Responses
- Mechanism for Recognition of CpG DNA
- CpG ODN As a Th1 Immune Enhancer for Prophylactic and Therapeutic Vaccines
- Modified Bacterial Toxins
- Glycosylphosphatidylinositol Anchors As Natural Immunological Adjuvants Derived From Protozoan Parasites
- The Immunomodulatory Glycan LNFPIII/Lewis X Functions As a Potent Adjuvant for Protein Antigens
- Immune and Antiviral Effects of the Synthetic Immunomodulator Murabutide
- Effects of QS-21 on Innate and Adaptive Immune Responses
- Monophosphoryl Lipid A and Synthetic Lipid A Mimetics As TLR4-Based Adjuvants and Immunomodulators
- Microparticles and DNA Vaccines.